Peptide Initiative

Peptides · Peptide comparison

BPC-157 vs Nesiritide (BNP)

The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.

Recombinant B-type natriuretic peptide that helps your heart breathe easier by reducing fluid overload and improving blood flow during acute heart failure crises.

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeBPC-157250–500 mcgNesiritide (BNP)0.01–0.01 mcg/kg/min
FrequencyBPC-157Once dailyNesiritide (BNP)Once daily
AdministrationBPC-157Subcutaneous injectionNesiritide (BNP)Intravenous (IV) bolus
Cycle lengthBPC-1574-6 weeksNesiritide (BNP)Ongoing/indefinite
Onset speedBPC-157Moderate (1-2 weeks)Nesiritide (BNP)Moderate (1-2 weeks)
Evidence levelBPC-157Strong preclinical (extensive animal studies)Nesiritide (BNP)Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Primary Benefit

BPC-15785%
Nesiritide (BNP)No recorded rating

Secondary Benefit

BPC-15778%
Nesiritide (BNP)No recorded rating

Additional Benefit

BPC-15772%
Nesiritide (BNP)No recorded rating

Rapid Symptom Relief

BPC-157No recorded rating
Nesiritide (BNP)95%

Fluid Management

BPC-157No recorded rating
Nesiritide (BNP)88%

Heart Workload Reduction

BPC-157No recorded rating
Nesiritide (BNP)90%

Technical data

Compound specifications

BPC-157

Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Half-life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS number
137525-51-0

Nesiritide (BNP)

Molecular formula
C143H244N50O42S4
Molecular weight
3464.0 Da
Half-life
18 minutes (terminal elimination half-life)
Bioavailability
100% (intravenous administration)
CAS number
114471-18-0

Protocols

Dosing compared

BPC-157

Subcutaneous

  • 250 mcgOnce daily · 1-2 weeksA common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
  • 250-500 mcgTwice daily · 4-6 weeksCommonly used range for tissue and tendon recovery in research practice [1][3].
  • 500 mcgTwice daily · 6-8 weeksUpper end used in practice for more demanding acute injuries [1][3].

Nesiritide (BNP)

Intravenous

  • 2 mcg/kg IV bolusSingle bolus at initiation · One-time loading doseFDA-approved Natrecor loading bolus given before the maintenance infusion [5][6]. May be omitted if hypotension risk is high.
  • 0.01 mcg/kg/min continuous infusionContinuous IV infusion · Typically up to 48 hoursFDA-approved maintenance infusion following the bolus [5][6]. Hospital-only with continuous blood-pressure monitoring.

Applications

Best suited for

BPC-157

Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]

Nesiritide (BNP)

Emergency stabilization of acute heart failure episodes
Nesiritide (BNP) is particularly well-suited for individuals focused on emergency stabilization of acute heart failure episodes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Rapid relief of severe shortness of breath
Nesiritide (BNP) is particularly well-suited for individuals focused on rapid relief of severe shortness of breath. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Short-term relief in hospital, not long-term outcome improvement
Nesiritide's benefit is short-term: it lowers lung pressures and eases breathlessness in the first hours of treatment [5]. In the 7,141-patient ASCEND-HF trial it did not reduce 30-day death or heart-failure rehospitalization (9.4% vs 10.1%), and it is not recommended for routine use [2][5].
Managing sudden fluid buildup in the lungs or legs
Nesiritide (BNP) is particularly well-suited for individuals focused on managing sudden fluid buildup in the lungs or legs. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

BPC-157

Common

  • Injection site redness
  • Mild nausea
  • Dizziness

Uncommon

  • Headache
  • Fatigue
  • Hot/cold sensations

Serious

  • Allergic reaction

Nesiritide (BNP)

Common

  • Headache
  • Lightheadedness
  • Back pain

Uncommon

  • Hypotension (low blood pressure)
  • Abdominal pain
  • Insomnia

Serious

  • Acute kidney injury
  • Severe hypotension
  • Allergic reaction

Research status

Safety & evidence

BPC-157

Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.

Contraindications

  • Pregnancy
  • Breastfeeding
  • Active cancer
  • History of cancer

Nesiritide (BNP)

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Nesiritide (Natrecor) was FDA-approved for acutely decompensated heart failure with breathlessness at rest or minimal activity [5]. Low blood pressure is the dose-limiting side effect: 12% of patients versus 4% on placebo in long-infusion trials, and symptomatic hypotension in 7.1% versus 4.0% in the 7,141-patient ASCEND-HF trial [2][5]. When it happens it can last longer than with nitroglycerin (mean 2.2 vs 0.7 hours), because the blood-pressure effect outlasts the drug's 18-minute half-life [5]. Serum creatinine rises more often than with placebo or nitroglycerin, so kidney function is monitored during and after treatment [5]. A pooled analysis of seven trials found no increase in 30- or 180-day mortality, and the trials showed no evidence of tolerance (tachyphylaxis) to its effects [5].

Contraindications

  • Persistent systolic blood pressure below 100 mmHg before treatment [5]
  • Cardiogenic shock [5] or severe hypotension
  • Allergy to nesiritide or any ingredients [5]

Decision guide

Which is right for you?

BPC-157

Choose BPC-157 if…

  • Injury recovery
  • Post-surgery healing
  • Chronic pain management
  • Gut health

Nesiritide (BNP)

Choose Nesiritide (BNP) if…

  • Emergency stabilization of acute heart failure episodes
  • Rapid relief of severe shortness of breath
  • Reducing hospitalization time and improving outcomes
  • Managing sudden fluid buildup in the lungs or legs